INTRODUCTION {#s1}
============

Gastric cancer (GC) is the fourth malignant tumor and the second leading cause of tumor related death in the world \[[@R1]\]. Patients with advanced GC has only a median overall survival (OS) of less than 12 months \[[@R2]--[@R3]\]. Therefore, there is an urgent need for reliable prognostic factors to predict poor prognosis and to subdivide different risk stratification for management of GC patients.

Ki-67 is a nuclear protein which expresses throughout the cell cycle in proliferating cells \[[@R4]\]. The correlation between Ki-67 expression and prognosis of GC patients were still contradictory \[[@R5]--[@R33]\]. Meanwhile, the clinicopathologic significance of Ki-67 expression in GC patients was uncertain. Therefore, we performed this meta-analysis to determine the clinicopathologic significance and prognostic value of Ki-67 expression in GC patients.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

The initial search returned 595 articles (with 75duplicate articles). After screening the abstracts, 445 irrelevant articles were excluded. Reviewers identified 75 potential studies for full-text review and 46 articles were eliminated due to inadequate data. Finally, 29 studies were included in the present study \[[@R5]--[@R33]\]. The details of screening process were shown in Figure [1](#F1){ref-type="fig"}.

![Flowchart of study selection in present meta-analysis](oncotarget-08-50273-g001){#F1}

Study selection and characteristics {#s2_2}
-----------------------------------

The characteristic of included studies were summarized in Table [1](#T1){ref-type="table"}. The publication time of included studies was between 1996 and 2016. The study sample size was between 56 and 693, with a mean sample size of 193. The NOS score of 29 studies varied from 7 to 8, with a mean value of 7.73. Twenty-three studies provided survival information and fifteen studies presented clinicopathologic parameters.

###### Characteristics of studies included in the meta analysis

  Study                              Type             Method   Cell   Cutoff point   Number   HR      95%CI Lower   95%CI upper   *P* value   NOS score
  ---------------------------------- ---------------- -------- ------ -------------- -------- ------- ------------- ------------- ----------- -----------
  Muller et al 1996\[[@R5]\]         GC               WTS      1000   53.30%         418      1.04    0.8           1.33          0.77        8
  Victorzon et al 1996\[[@R6]\]      GC               WTS      1000   30%            237      1.1     0.78          1.55          0.587       8
  Ohtani et al 1998\[[@R7]\]         GC               WTS      NR     35.90%         225      1.307   0.777         2.199         0.313       8
  Manzoni et al 1998\[[@R8]\]        GC               WTS      1000   10%            56       NR      NR            NR            NR          7
  Ikeguchi et al 1999\[[@R9]\]       GC               WTS      1000   18%            97       1.023   0.994         1.055         0.121       8
  Liu et al 2001\[[@R10]\]           GC               WTS      1000   27%            190      NR      NR            NR            NR          7
  Al-Moundhri et al 2005\[[@R11]\]   GC               WTS      1000   25%            121      NR      NR            NR            NR          7
  Takahashi et al 2006\[[@R12]\]     GC               WTS      1000   50%            122      0.99    0.48          2.05          0.978       8
  Takahashi et al 2009\[[@R13]\]     GC               WTS      1000   25%            71       1.25    0.55          2.86          0.594       8
  Tsamandas et al 2009\[[@R14]\]     GC               WTS      NR     5%             110      2.93    1.69          5.08          0.001       8
  Tzanakis et al 2009\[[@R15]\]      GC               WTS      NR     35%            93       1.48    0.86          2.54          0.157       7
  Li et al 2009\[[@R16]\]            GC               WTS      1000   10%            336      2.55    1.8           3.62          0.001       8
  Lazar et al 2010\[[@R17]\]         GC               WTS      500    45%            61       1.07    0.62          1.84          0.808       8
  Lee et al 2010\[[@R18]\]           GC               WTS      300    10%            245      0.561   0.38          0.83          0.004       8
  Zhao et al 2010\[[@R19]\]          GC               WTS      1000   50%            336      NR      NR            NR            NR          7
  Ichinoe et al 2011\[[@R20]\]       GC               WTS      1000   40%            87       0.907   0.532         1.547         0.720       8
  Nakashima et al 2011\[[@R21]\]     Adenocarcinoma   WTS      1000   48.10%         100      NR      NR            NR            NR          7
  Wen et al 2011\[[@R22]\]           GC               TMAS     1000   10%            264      2.56    1.39          5.62          0.003       8
  Giaginis et al 2011\[[@R23]\]      GC               WTS      1000   50%            66       NR      NR            NR            NR          7
  He et al 2012\[[@R24]\]            GC               TMAS     1000   25%            166      1.85    1.3           2.63          0.001       8
  Kang et al 2013\[[@R25]\]          GC               WTS      NR     10%            458      0.63    0.37          1.08          0.089       8
  Liu et al 2013\[[@R26]\]           GC               WTS      NR     50%            180      3.44    1.7           6.96          0.001       8
  Xiao et al 2013\[[@R27]\]          GC               TMAS     500    1%             43       1.32    0.91          1.9           0.143       8
  Yang et al 2014\[[@R28]\]          Adenocarcinoma   WTS      1000   30%            159      1.13    0.63          2.05          0.682       8
  Ayed et al 2014\[[@R29]\]          GC               WTS      1000   1%             90       NR      NR            NR            NR          7
  Li et al 2015\[[@R30]\]            GC               WTS      NR     50%            69       1.5     0.59          3.71          0.394       8
  Boger et al 2016\[[@R31]\]         GC               WTS      500    50%            315      1.08    0.88          1.33          0.461       7
  Huang et al 2016\[[@R32]\]         Adenocarcinoma   WTS      NR     50%            693      1.421   1.191         1.695         0.001       8
  Ou et al 2016\[[@R33]\]            Adenocarcinoma   TMAS     NR     5%             192      1.1     0.9           1.35          0.352       8

HR, hazard ratio; CI, confidence interval; NOS, Newcastle-Ottawa Quality Assessment Scale.

Association of Ki-67 expression with clinicopathologic parameters {#s2_3}
-----------------------------------------------------------------

As shown in Figure [2](#F2){ref-type="fig"}, high Ki-67 expression was significantly related with Lauren\'s classification (OR = 1.70; *P* = 0.001; 95%CI: 1.40-2.06) and tumor size(OR = 1.54; *P* = 0.006; 95%CI: 1.14-2.09). However, high Ki-67 expression was not significantly associated with lymph node metastasis (OR = 1.37; *P* = 0.138; 95% CI: 0.90-2.08), tumor stage (OR = 1.31; *P* = 0.296; 95% CI: 0.79-2.16) and tumor differentiation (OR = 1.03; *P* = 0.839; 95% CI: 0.78-1.35).

![Forest plot diagrams of odds ratios for correlations between Ki-67 expression and pathological parameters](oncotarget-08-50273-g002){#F2}

Prognostic value of high Ki-67 expression in gastric cancer patients {#s2_4}
--------------------------------------------------------------------

A total of 4741 GC patients from 23 eligible studies were included and analyzed for prognostic value of Ki-67 expression in GC patients(Figure [3and](#F3){ref-type="fig"} Figure [4](#F4){ref-type="fig"}). The pooled HRs was 1.87(*P* = 0.001; 95% CI 1.30-2.69) for DFS and 1.23(*P* = 0.005; 95% CI 1.06-1.42) for OS.

![Forest plot diagrams of hazard ratios for correlations between Ki-67 expression and overall survival](oncotarget-08-50273-g003){#F3}

![Forest plot diagrams of hazard ratios for correlations between Ki-67 expression and disease free survival](oncotarget-08-50273-g004){#F4}

Sensitivity analysis {#s2_5}
--------------------

All studies were sequentially removed to explore that whether any individual study had an significant influence to the pooled HR. The pooled HR in sensitivity meta-analysis ranged from 1.17(95%CI: 1.02-1.34) to 1.28 (95%CI: 1.11-1.48) for OS, demonstrating that the pooled HR was not significantly affected by any individual study(Table [2](#T2){ref-type="table"}).

###### Effect of individual studies on the pooled HRs of Ki-67 expression for overall survival

  Study omitted   Estimate HR   95%CI       
  --------------- ------------- ----------- -----------
  1               1.2472792     1.0675433   1.4572761
  2               1.240342      1.0646844   1.4449806
  3               1.2284332     1.0576263   1.4268255
  4               1.2592941     1.0504285   1.5096903
  5               1.243209      1.0714135   1.4425511
  6               1.2308739     1.0614478   1.4273434
  7               1.1883517     1.03158     1.3689484
  8               1.2223002     1.0531162   1.4186638
  9               1.1733439     1.0239507   1.3445334
  10              1.238404      1.0660043   1.4386851
  11              1.2813864     1.1075524   1.4825042
  12              1.2639937     1.0909787   1.4644465
  13              1.2044084     1.0418602   1.3923169
  14              1.2009488     1.0375293   1.3901081
  15              1.2637651     1.0899976   1.4652347
  16              1.1940765     1.0359601   1.376326
  17              1.2269805     1.0546938   1.4274106
  18              1.2353078     1.063794    1.4344743
  19              1.2264266     1.0582221   1.4213671
  20              1.2459158     1.0632767   1.4599268
  21              1.2191019     1.0452053   1.4219306
  22              1.2612625     1.0773629   1.4765527
  Combined HR     1.2309021     1.0641824   1.4237409

HR, hazard ratio; CI, confidence interval.

Publication bias {#s2_6}
----------------

The figure of Begg\'s funnel plot (Figure [5](#F5){ref-type="fig"}) did not show any evidence of asymmetry for OS (*P* = 0.499). Similarly, there were no evidences for publication bias in terms of Lauren\'s classification (*P* = 0.721), tumor size(*P* = 0.881), lymph node metastasis (*P* = 0.788), tumor stage (*P* = 1.0) and tumor differentiation (*P* = 0.734). The further Egger\'s linear regression test did not find any significant evidences of publication bias for Lauren\'s classification (*P* = 0.435), tumor size(*P* = 0.586), lymph node metastasis (*P* = 0.750), tumor stage (*P* = 0.627), tumor differentiation (*P* = 0.652) and OS(*P* = 0.066).

![Begg\'s funnel plot for studies which provided hazard ratios of high Ki-67 expression for overall survival (*P* = 0.499)](oncotarget-08-50273-g005){#F5}

Stability assessment of the pooled hazard ratios of Ki-67 expression for overall survival by cumulative meta-analysis {#s2_7}
---------------------------------------------------------------------------------------------------------------------

The pooled HRs of cumulative meta-analysis(Figure [6](#F6){ref-type="fig"}) ranged from 1.23(95%CI: 1.06-1.42) to 1.27 (95%CI: 1.04-1.56) for OS since 2013, demonstrating that performance of Ki-67 expression for OS in GC patients was stable and reliable.

![Cumulative meta-analysis for stability of the hazard ratios of Ki-67 for overall survival in gastric cancer patients](oncotarget-08-50273-g006){#F6}

Explore of sources of heterogeneity by meta-regression analyses and subgroup analyses {#s2_8}
-------------------------------------------------------------------------------------

The pooled HR was 1.31(95% CI 1.05-1.62; *P* = 0.017; heterogeneity = 82.7%; *P* \< 0.001) in studies with patient number more than 100 for OS whereas it was 1.08(95% CI 0.91-1.28; *P* = 0.386; heterogeneity = 26.3%; *P* \< 0.228) in studies with patient number not more than 100(Table [3](#T3){ref-type="table"}). The results suggested that sample size might contributed to the clinical heterogeneity. However, meta-regression analysis did not find any source of heterogeneity (all *P* \> 0.05, data not shown).

###### Subgroup analyses for associations between Ki-67 expression and overall survival in gastric cancer patients

                                   Overall survival   95%CI   Heterogeneity                  
  ------------------- ------- ---- ------------------ ------- --------------- ------ ------- -------
  Total               Total   22   1.23               0.005   1.06            1.42   79.7%   0.001
  patients≥100        Yes     15   1.31               0.017   1.05            1.62   82.7%   0.001
                      No      7    1.08               0.386   0.91            1.28   26.3%   0.228
  Adenocarcinoma      Yes     3    1.14               0.476   0.80            1.62   81.3%   0.005
                      No      19   1.26               0.01    1.06            1.50   80.0%   0.001
  THAS                Yes     3    1.45               0.096   0.94            2.25   83.1%   0.001
                      No      19   1.19               0.037   1.01            1.41   79.7%   0.001
  Cell number=1000    Yes     10   1.27               0.057   0.99            1.62   81.0%   0.001
                      No      4    0.97               0.847   0.69            1.36   73.2%   0.011
  Cut-off point≥25%   Yes     14   1.24               0.01    1.05            1.46   53.0%   0.01
                      No      8    1.24               0.143   0.93            1.66   88.8%   0.001

HR, hazard ratio; CI, confidence interval.

DISCUSSION {#s3}
==========

The current meta analysis showed that high Ki-67 expression was significantly related with Lauren\'s classification (OR = 1.70; 95%CI: 1.40-2.06) and tumor size (OR = 1.54; 95%CI: 1.14-2.09). The pooled HRs were 1.87(95% CI 1.30-2.69) for DFS and 1.23(95% CI 1.06-1.42) for OS. These results demonstrated that high Ki-67 expression significantly predicts poorer prognosis compared with low Ki-67 expression.

Some previous studies have reported that high Ki-67 expression was associated with poor OS in GC patients\[[@R14], [@R16], [@R22], [@R24], [@R26], [@R32]\]. These original studies have revealed that high Ki-67 expression had a predictive value for prognosis of GC patients. Our conclusion was consistent with that of these previous studies. Recently, several meta analyses have reported that high Ki-67 expression was associated with poor prognosis in different tumors, including gastrointestinal stromal tumor, cervical cancer and non-small cell lung cancer \[[@R35]--[@R37]\]. Furthermore, two studies have further reported that Ki-67 expression could be used for risk stratification in patients with gastrointestinal stromal tumor \[[@R38]--[@R39]\].

The heterogeneity was significant in the present meta-analysis. There might be some potential sources of heterogeneity as follows: First, the heterogeneity caused by different cut-off values of Ki-67 expression was inevitable. Second, subgroup analyses showed that sample size might be a potential source of heterogeneity. Third, the identify methods of Ki-67 expression (TMAS or WTS) and the number of count cells(1000 or 500) might yield variation in different studies. In addition, heterogeneity could be caused by other factors, such as study regions, pathology types, tumor stages, treatments and races.

Although significant heterogeneity existed in the present meta-analysis, sensitivity analyses and cumulative meta-analyses demonstrated that HRs of Ki-67 expression for prognosis of GC patients was stable and reliable. Furthermore, we performed Begg\'s funnel plot and Egger\'s test to assess the potential publication bias and did not find any evidence of publication bias.

The present meta analysis had several strengths: Firstly, we first explored the association between Ki-67 expression and clinicopathologic parameters in GC patients. Secondly, we included 29 eligible studies and 5600 patients, which could strengthen persuasiveness of the conclusions. Thirdly, Ki-67 expression in 29 eligible studies was all detected by IHC. Fourthly, studies published in Chinese were included as English literature to increase representation of study population.

The results of the present meta analysis need to be interpreted cautiously for several limitations. First, most studies defined positive status of Ki-67 expression according to different cut-off values. Second, heterogeneity was inevitable due to different baseline characteristics. Third, although the method for extracting survival information from survival curve is widely accepted, we could not completely eliminate the sources of information inaccuracy in the process of extracting data.

In conclusion, high Ki-67 expression may serve as a predictive biomarker for poor prognosis in gastric cancer patients. Stratification by Ki-67 expression may be a consideration for selection of therapeutic regimen and integrated managements.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

Several electronic databases, including PubMed, EMBASE, Cochrane Library, Web of Knowledge, China National Knowledge Infrastructure and WanFang data, were searched from January 1970 to May 2016. We performed literature search by combined text word and MeSH(Emtree for EMBASE database accordingly) strategy with terms " Ki-67 Antigen" or "MIB-1 Antigen" and "gastric cancer" or "gastric carcinoma" or "stomach tumor" and "survival" or "outcome" or "prognosis" or "prognostic". The strategy was correspondingly adjusted in different databases. In the retrieval process, expanded search of hyponym was performed. We made a manual search using the reference lists of the relevant articles. We contacted the corresponding author to get necessary information if necessary. The search was restricted to human studies, but there was no restriction on language or publication time. All clinical investigation and data achievement were conducted according to the principles expressed in the Declaration of Helsinki.

Criteria for inclusion and exclusion {#s4_2}
------------------------------------

The inclusion criteria were as follows: (1) proven pathological diagnosis of GC in humans; (2) Ki-67 expression evaluation using immunohistochemistry (IHC) method; (3)provided information on clinicopathological parameters and/or overall survival information. Studies not directly providing survival information were included if survival information were available from survival curve. Articles published in Chinese were included as English literature. Only the most recent study was included among duplicate studies. There were no restrictions on sample size or follow-up period.

The following studies were excluded: (1) reviews, letters, case reports, and conference abstracts without original data; (2) non-human experiments; (3) laboratory studies; (4) articles from which the necessary information could not be extracted.

Quality assessment of studies {#s4_3}
-----------------------------

Two reviewers (Zhiqiao Zhang and Jinxin Lin) independently assessed the quality of studies using the Newcastle-Ottawa Quality Assessment Scale(NOS) (Table [1](#T1){ref-type="table"}). Disagreements were resolved through consensus with a third reviewer (Guanying Luo).

Data extraction {#s4_4}
---------------

Two investigators (Zhiqiao Zhang and Jinxin Lin) independently extracted and examined the following data: surname of the first author, publication year, country, sample size, disease stage, detection method of Ki-67, clinical parameters and survival outcome data. Study information was extracted and recorded using a standardized form. All eligible studies were coded as surname of the first author + publish year in the standardized form. Study authors were contacted to obtain key information if necessary. When necessary, a third investigator (Guanying Luo) helped to reach a consensus.

Statistical analysis {#s4_5}
--------------------

The statistical analysis was performed according to the guidelines suggested by the Meta-Analysis of Observational Studies in Epidemiology group(MOOSE)\[[@R34]\]. The pooled odds ratio (OR) were combined to explore the association between KI-67 expression and clinicopathological parameters. The pooled hazard ratio (HR) were used to summary outcome of overall survival. While survival data were not directly reported, we extracted survival information from Kaplan-Meier curve. The heterogeneity among different studies was measured by the Q and *I*^2^ tests. A probability value of *I*^2^ ≥30% and *P* \< 0.1 indicated the existence of significant heterogeneity. A random effect model (DerSimonian and Laird method) or fixed effect model(Mantel-Haenszel method) was used depending on the results of heterogeneity analysis. The potential publication bias was assessed by Begg\'s funnel plot and Egger\'s test. *P* value \< 0.05 was considered statistically significant. The statistical analyses were performed by STATA version 12.0 software (Stata Corporation, College Station, Texas, USA).
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